Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Bariatric surgery leads to bone loss and increases fracture risk. This study evaluates
whether denosumab can prevent the high-turnover bone loss that occurs after Roux-en-Y Gastric
Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
San Francisco VA Health Care System University of California, San Francisco